Daxor Director Granted 2,500 Options at $9.29 – Insider Filing
Daxor (DXR) filed a routine Form 4 disclosing that director Henry D. Cremisi received an option grant for 2,500 common-stock shares on June 24 2025 under the company’s 2020 Incentive Compensation Plan, contingent upon SEC approval of an amendment to that plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Daxor (DXR) filed a routine Form 4 disclosing that director Henry D. Cremisi received an option grant for 2,500 common-stock shares on June 24 2025 under the company’s 2020 Incentive Compensation Plan, contingent upon SEC approval of an amendment to that plan. The options carry a $9.29 exercise price and vest in three annual tranches (833/883/834 shares through 2027). No DXR shares were bought or sold, and Cremisi’s beneficial ownership now includes the new grant. The filing does not report any other transactions or material changes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 2,500 | $0.00 | $0.00 |
Footnotes (2)
- F1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
- F2. The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834)
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DXR report on June 29 2025?
AI-generated analysis. How Rhea-AI works. Not financial advice.